Pathological progression induced by the frontotemporal dementia-associated R406W tau mutation in patient-derived iPSCs

Mari Nakamura

Celeste M Karch

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs

Mari Nakamura,1,2 Seiji Shiozawa,1,* Daisuke Tsuboi,3 Mutsuki Amano,3 Hirotaka Watanabe,1 Sumihiro Maeda,1 Taeko Kimura,4 Sho Yoshimatsu,1 Fumihiro Kisa,1 Celeste M. Karch,5 Tomohiro Miyasaka,6 Akihiko Takashima,7 Naruhiko Sahara,4 Shin-ichi Hisanaga,8 Takeshi Ikeuchi,9 Kozo Kaibuchi,3 and Hideyuki Okano1,(*)

1Department of Physiology, School of Medicine, Keio University, 35 Shinnanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
2Department of Biomedical Chemistry, School of International Health, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, Japan
3Department of Cell Pharmacology, Graduate School of Medicine, Nagoya University, 65 Tsurumai, Showa, Nagoya, Aichi 466-8550, Japan
4Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 266-8555, Japan
5Department of Psychiatry and Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA
6Department of Neuropathology, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe-shi, Kyoto 610-0394, Japan
7Faculty of Science, Gakushuin University, Toshima-ku, Tokyo 171-8588, Japan
8Department of Biological Sciences, Graduate School of Science, Tokyo Metropolitan University, 1-1 Minami-Osawa, Hachioji-shi, Tokyo 192-0397, Japan
9Department of Molecular Genetics, Brain Research Institute, Niigata University, 1-757 Asahimachidori, Chuo-ku, Niigata 951-8585, Japan

*Correspondence: shiozawa@keio.jp (S.S.), hidokano@keio.jp (H.O.)

https://doi.org/10.1016/j.stemcr.2019.08.011

SUMMARY

Mutations in the microtubule-associated protein tau (MAPT) gene are known to cause familial frontotemporal dementia (FTD). The R406W tau mutation is a unique missense mutation whose patients have been reported to exhibit Alzheimer’s disease (AD)-like phenotypes rather than the more typical FTD phenotypes. In this study, we established patient-derived induced pluripotent stem cell (iPSC) models to investigate the disease pathology induced by the R406W mutation. We generated iPSCs from patients and established isogenic R406W iPSC lines, but those conducting phenotype

INTRODUCTION

Frontotemporal dementia (FTD) is one of the most common types of early-onset dementia after Alzheimer’s disease (AD). In some familial cases, it is caused by mutations in the microtubule-associated protein tau (MAPT) gene, which encodes the tau protein [Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998]. Over 50 mutations on the MAPT gene have been reported to cause FTD [Ghetti et al., 2015], and the patients exhibit diverse clinical phenotypes [Ghetti et al., 2011]. The R406W missense mutation is one such pathological mutation located on exon 13 of the MAPT gene [Hutton et al., 1998; Rizzu et al., 1999; Van Swieten et al., 1999]. Interestingly, patients with this mutation have been reported to exhibit AD-like phenotypes: early memory impairment is a primary presenting feature, while the more typical FTD symptoms, including changes in social behavior and personality, as well as motor symptoms [Foster et al., 1997], are less predominant or not seen at all [Ikeuchi et al., 2011].

As of today, there is no effective treatment for FTD patients. It is crucial to gain a better understanding of the disease pathogenesis for the development of novel therapeutic strategies. Previous studies using transgenic murine models and postmortem patient brains have yielded significant insights into the disease mechanism, but each have their own shortcomings. The former model has not been able to completely recapitulate human disease pathology, possibly due to species differences and overexpression of the tau transgene in irrelevant brain areas [Denk and Wade-Martins, 2009], and the latter cannot model disease onset or progression, and cannot be easily accessed for research purposes due to ethical limitations. Thus, there is a need for a model that is readily accessible and can accurately recapitulate the disease pathogenesis. Recently, considerable attention has been given to the potential of human induced pluripotent stem cell (iPSC) technology [Takahashi et al., 2007] for disease modeling. Human iPSCs have the potential to differentiate into neurons, which have previously been difficult to obtain. Using this model could thereby provide us with a deeper understanding of the molecular mechanism of the disease onset and progression.

Previously there have been reports on the generation of MAPT R406W iPSC lines, but those conducting phenotype
analysis at the molecular level have been limited (Jiang et al., 2018; Nimsanor et al., 2016a, 2016b; Rasmussen et al., 2016a, 2016b). On the one hand, Imamura et al. (2016) has observed an accumulation of misfolded tau, calcium dysregulation, and neuronal cell death in FTD iPSC models, including those carrying the R406W mutation, but as these phenotypes were commonly found in neurons with other tau mutations as well, the pathological mechanism specific for the R406W mutation remains unexplored.

Here, we sought to establish a model that can recapture the disease pathogenesis induced by the R406W mutation, as a basis for therapeutic development for tauopathies including FTD and AD. Using neurons differentiated from patient-derived iPSCs and their corresponding isogenic lines, we identified the biochemical changes of tau induced by the R406W mutation and their effects at the cellular level.

RESULTS

Generation and Characterization of the MAPT R406W iPSCs

MAPT R406W iPSCs were established from two Japanese FTD patients (patients #1 and #2) of the same pedigree, whose primary symptom was memory impairment (Ikeuchi et al., 2011; Table S1). DNA sequencing confirmed that the patients were heterozygous for the mutation (MAPT<sup>R406W/+</sup>, Figure 1D; Ikeuchi et al., 2011). The patients had no other mutations besides the MAPT R406W mutation, as previously confirmed (Ikeuchi et al., 2011).

The iPSCs were generated by using the integration-free episomal vector system, as described previously (Ichiyanagi et al., 2016; Nakamoto et al., 2018; Okita et al., 2013). PCR analysis confirmed the removal of the episomal vectors from several clones (Figure S1A). These clones stained positively for the pluripotency markers alkaline phosphatase (Figure 1A) and TRA-1-60 (Figure 1B) and were karyotypically normal (Figure S1B).

We utilized another MAPT R406W iPSC line generated with Sendai virus vectors from a symptomatic subject of an unrelated pedigree (patient #3), who was also heterozygous for the mutation (Jiang et al., 2018; Table S1). The 201B7 iPSC line, derived from a healthy subject, was obtained for use as a control for subsequent experiments (Takahashi et al., 2007).

Generation of Isogenic iPSC Lines with CRISPR/Cas9

Next, we utilized CRISPR/Cas9 technology to manipulate the mutation site for the generation of isogenic lines (Cong et al., 2013) in order to reduce the variability of experiments caused by genetic heterogeneity. Targeting vectors were designed to include the mutation site on the 3’ arm and a selection cassette in between the two arms, with PiggyBac inverted terminal repeats at both ends to enable footprint-free excision (Figure 1C). Transfection experiments were performed, and colonies that survived drug selection were picked up and analyzed. Consequently, DNA sequencing revealed the successful manipulation of the mutation site, confirming the generation of isogenic wild-type (WT) MAPT<sup>+/−</sup> lines and homozygous mutant (MAPT<sup>R406W/R406W</sup>) lines (Figure 1D). Finally, the gene-edited clones were transfected with the PiggyBac transposase for the excision of the selection cassette (Nakamoto et al., 2018). DNA-sequencing analysis in the manipulated region confirmed that these isogenic clones were free of genomic indels and other unintended mutations (Figure S1C).

Establishment of iPSC-Derived Neuron-Rich Culture via Dissociation of Cerebral Organoids

The iPSC lines were then subjected to neuronal differentiation for subsequent analysis (Figure 2A). We utilized the method for inducing cerebral organoids (Kadoshima et al., 2013; Lancaster et al., 2013), since previous reports have implicated that three-dimensional (3D) cultures may accelerate disease pathology compared with conventional two-dimensional (2D) cultures (Choi et al., 2014). However, because cerebral organoids consist of a heterogeneous population of cells (Quadrato et al., 2017) and the cells within the organoids are densely packed, we found that the use of cerebral organoids as a whole was not suitable for biochemical analyses and morphological observations of neurons. Thus, we devised a method to isolate a pure population of cortical neurons from the organoids.

Figure 1. Generation and Characterization of iPSCs from FTD MAPT R406W Patients

(A and B) Immunofluorescence for pluripotency markers alkaline phosphatase (A) and TRA-1-60 (B). Representative clones from each patient are shown. Scale bars, 500 μm.

(C) Schematic diagram of the construction of targeting vectors. Top: construct of the WT targeting vector for the generation of WT lines. Bottom: construct of the mutant targeting vector for the generation of homozygous mutant lines.

(D) DNA sequence of the mutation site in the heterozygous patient line (MAPT<sup>R406W/+</sup>) and in the gene-edited isogenic lines (WT line: MAPT<sup>+/−</sup>, homozygous mutant line: MAPT<sup>R406W/R406W</sup>).

See also Figure S1.
After 30 days of culture, we dissociated the organoids onto typical 2D culture dishes and cultured them for an additional 30 days, at which point these cultures were evaluated by immunofluorescence. Lines that were successfully induced into organoids and dissociated consisted of neurons positive for MAP2, TBR1, and tau (Figure 2B). Quantification revealed that all the lines evaluated were >85% positive for neuronal markers MAP2 and βIII-tubulin (Figures 2C and 2D), and also highly positive for forebrain (cortical neuron) markers TBR1 and FOXG1, as well as NeuN, indicating the presence of mature neurons (Figures 2E–2G), with similar differentiation efficiency among lines. The yield of live cells from one dissociated organoid of any given line was approximately 4 × 10^5 cells (equivalent to the number of cells plated onto one well of a 12-well plate), the majority of which we assumed to be neurons (Figure 2H).

Unfortunately, because all the iPSC lines derived from patient #1 did not efficiently differentiate into neurons with our protocol, we focused on using iPSC-derived neurons from patients #2 and #3 for the subsequent analyses.

**R406W Mutant Tau Is Less Phosphorylated by Multiple Kinases**

Tau hyperphosphorylation is a key hallmark of tauopathies (Spillantini and Goedert, 2013). Interestingly, western blot analysis revealed that tau phosphorylation at S409 and T181 were lowered in both MAPT*R406W* and MAPT*R406W*/R406W neurons compared with the control neurons 30 days after dissociation (Figures 3A–3D, S2A, and S2B). The phosphorylation level of S404 also appeared to decrease when analyzed with an S404 phosphorylation-dependent tau antibody (Figures S2C and S2D), as previously reported (Sakaue et al., 2005). However, reduced phosphorylation was not observed with the PHF1 antibody, which recognizes both S396 and S404 (data not shown), suggesting that the reduction seen with the S404 phosphorylation-specific antibody may simply be reflecting a change in immunogenicity due to the mutation. Tau phosphorylation levels were already reduced even at an earlier time point of 10 days post dissociation (Figures S5A–S5C). Furthermore, co-expression of the glutathione S-transferase-conjugated C-terminal fragment of WT or R406W tau with various kinases in vitro revealed that the mutation impaired the phosphorylation of S404 by GSK3β and CDK5 and the phosphorylation of S409 by Rho-associated protein kinase (RhoK) and protein kinase A (PKA) (Figure S3A). These findings support the results obtained with the iPSC-derived neurons and suggest that the R406W mutation potentially impairs the phosphorylation of tau by multiple kinases.

In addition, when blotting with pan-tau antibody Tau5, we found that the samples exhibited two major bands (48 kDa and 55 kDa). The intensity of the 48-kDa band was increased in the mutant samples derived from patients #2 and #3 at both 10 days and 30 days after dissociation (Figures 3E–3H, S2F, S2H, S5D, and S5E). The two bands differed in the phosphorylation level of tau, with the 48-kDa band representing the less phosphorylated form of tau (hereafter termed “hypophosphorylated” tau), since both bands shifted downward and merged into one band representing the 0N3R tau isoform when the samples were treated with λ-phosphatase for dephosphorylation (Figure S2G). Furthermore, the amount of 48-kDa tau increased with GSK3β inhibition using SB216763, which implicates GSK3β as the kinase most responsible for the reduced phosphorylation levels of R406W mutant tau (Figures 3G and 3H). In support of our finding, treatment with CHIR99021, a more specific GSK3β inhibitor, resulted in a dose-dependent increase of the 48-kDa band (Figures S3B and S3C). This is consistent with the results obtained when co-expressing tau and various kinases in COS-7 cells, showing that S404 and S409 are also potential phosphorylation sites of GSK3β and that their phosphorylation by GSK3β is impaired in the R406W mutation (Figures S3D–S3F). Importantly, the phosphorylation level of β-catenin, another major GSK3β substrate, remained unchanged, implying that the reduced tau phosphorylation was not due to a change in GSK3β activity but rather a change in accessibility to the tau protein because of the mutation (Figures S3G and S3H).
Figure 3. Reduction of Phosphorylation in R406W Mutant Tau by Multiple Kinases

(A–D) Western blot analysis investigating tau phosphorylation levels at S409 (A) or T181 (C). Both pS409 and pT181 levels were significantly reduced in the R406W mutant samples (S409, B; T181, D) relative to total tau levels (K9JA) (n = 2–3 independent experiments).

(E and F) Western blot analysis with pan-tau antibody Tau5 (E) revealed an increase in the ratio of 48-kDa tau (arrowhead) to total tau (both 48-kDa and 55-kDa bands) in the R406W mutant sample (F) (n = 3–4 independent experiments).

(legend continued on next page)
The phosphorylation state of tau is known to be regulated by a balance between kinases and phosphatases. To determine whether changes in phosphate activity were involved in the decrease in tau phosphorylation, we measured PP2A activity in our cells, but did not find differences among the control and mutant samples (Figure S3I).

Collectively, our analyses suggest that the R406W mutant tau was less phosphorylated by multiple kinases, with poor phosphorylation by GSK3β particularly accounting for the overall reduction of phosphorylation.

**Increased Fragmentation of R406W Tau by Calpain**

Tau is reportedly cleaved by several proteases to produce tau fragments of different lengths (Chesser et al., 2013). Western blot analysis revealed an increase in tau fragments ranging from 35 to 45 kDa in the R406W mutant samples across various epitopes (Figures 4A, 4B, and S4A–S4D). This was especially evident when blotting with Tau12, which recognizes the N terminus of tau, implying that the mutation particularly increases the generation of N-terminal tau fragments (Figures 4A and 4B). Next, we attempted to identify the protease generating these fragments. Neurons were treated either with a pan-caspase inhibitor (Z-FAD-VMK) or pan-calpain inhibitor (ALLN). Western blot analysis revealed a decrease of the 35-kDa fragment in samples treated with the calpain inhibitor, but not the caspase inhibitor (Figures 4C and 4D), indicating that calpain was generating the specific fragment. Interestingly, blotting with Tau5 revealed that the amount of hypophosphorylated tau (48 kDa) increased with calpain inhibition (Figures 4E and 4F). We presumed that the hypophosphorylated tau was mainly fragmented by calpain and that the reduction of phosphorylation caused by the R406W mutation made the mutant tau more susceptible to calpain cleavage.

**R406W Mutation Induces Tau Mislocalization and Axonal Dystrophy by Microtubule Destabilization**

Dissociated neurons were further examined for phenotypes at the cellular level. Immunofluorescence of the neurons with tau and MAP2 revealed an increased colocalization of the two markers in the mutant neurons (Figure 5A). Quantitative analysis confirmed that the mutant neurons had a small but significant increase of tau on MAP2-positive dendrites at 30 days after dissociation (Figure 5B). These results suggest that the R406W mutant tau is more likely to mislocalize from the axons to the dendrites of the neurons.

The morphology of the neurons was also investigated with immunofluorescence. Immunostaining with βIII-tubulin revealed a considerable number of dystrophic neurites in the mutant neurons (Figure 5C). Such a staining pattern was not observed with MAP2, indicating that the axons, but not the dendrites, were undergoing degeneration. At 30 days post dissociation, the axons of the mutant neurons consisted of a significantly greater number of small puncta (Figures 5D and 5E). Tau mislocalization and axonal dystrophy were not observed at an earlier time point of 10 days post dissociation (Figures S5F and S5G).

Interestingly, there were fewer axonal puncta when the mutant neurons were treated with Epothilone D (EpoD), a microtubule (MT) stabilizer (Figures 5D and 5E). Altogether, these results suggest that the R406W mutant tau may cause axonal degeneration by altering MT dynamics and/or stability.

**MT Destabilization Disrupts Mitochondrial Transport in the Mutant Neurons**

Because axonal degeneration occurred in the mutant neurons, we presumed that the function of the axons in these neurons may be disrupted as well. Axonal transport is one such process responsible for carrying organelles and proteins within neurons. Transport of mitochondria is particularly important, because neurons have high energy demands and require a large supply of ATP to maintain their function and survival (Schwarz, 2013). As such, mitochondrial dysfunction has been implicated during the early stages of multiple neurodegenerative diseases (Lin and Beal, 2006). Thus, we decided to investigate whether there were any defects in mitochondrial transport. After transfecting neurons with Mito-eYFP and tdTomato, we performed live-imaging analysis of the mitochondria in intact axons. We found mitochondria in the mutant neurons to be less stationary and moving more in the retrograde direction (Figure 6A). In support of our finding, fewer mitochondria were in the mutant neurons compared with those in the WT neurons, which again was rescued with EpoD treatment (Figures 6B and 6C). Overall, these results suggest that the R406W tau-induced MT destabilization caused impairment of the axonal transport machinery.

---

(G and H) Western blot analysis investigating the effects of kinase inhibitors SB216763, KT5720, Y27632, and Roscovitine (inhibitors of GSK3β, PKA, RhöK, and CDK5, respectively) on the phosphorylation pattern of tau in WT (20187) iPSC-derived neurons (G). Quantification of the ratio of 48-kDa tau to total tau (both 48-kDa and 55-kDa bands) revealed an increase of the ratio with SB216763 treatment, a GSK3β inhibitor, in comparison with that with the mock treatment of DMSO (H) (n = 3 independent experiments). Error bars indicate mean ± SEM. One-way ANOVA followed by Tukey’s test was performed. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S2, S3, and S5.
Figure 4. Increased Cleavage of Tau by Calpain Is Dependent on the Phosphorylation State

(A and B) Western blot analysis with pan-tau antibody Tau12 (A) revealed increased tau fragments ranging from 35 to 45 kDa (bracket) relative to full-length (FL) tau (brace) in the R406W mutant samples (B) (n = 3 independent experiments).

(C and D) Western blot analysis of MAPT<sup>R406W/R406W</sup> samples with Tau12 when treated with 120 μM Z-VAD-FMK (pan-caspase inhibitor), 250 μM ALLN (pan-calpain inhibitor), or DMSO (mock) (C) revealed a decreased ratio of 35-kDa tau fragments (arrow) to full-length (FL) tau (brace) with calpain inhibition (D) (n = 3 independent experiments).

(E and F) Western blot analysis of MAPT<sup>R406W/R406W</sup> samples with Tau5 when treated with 120 μM Z-VAD-FMK (pan-caspase inhibitor), 250 μM ALLN (pan-calpain inhibitor), or DMSO (mock) (E) revealed an increased ratio of hypophosphorylated tau (48 kDa; arrowhead) to total tau (both 48-kDa and 55-kDa bands) with calpain inhibition (F) (n = 3 independent experiments).

Error bars indicate mean ± SEM. One-way ANOVA followed by Tukey’s test was performed. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S4.
DISCUSSION

The role of tau in neurodegeneration has been extensively studied using various models. Development of tau transgenic animal models and cell-line models has provided fundamental insight of tau under both physiological and pathological conditions (Denk and Wade-Martins, 2009; Lim et al., 2014). In the case of R406W mutant tau, hyperphosphorylation and aggregation of tau into filament-like structures (Ikeda et al., 2005; Tatebayashi et al., 2002), as well as retardation of axonal transport (Zhang et al., 2004), has been reported in R406W tau transgenic mice. In cell-line models, soluble R406W tau was less phosphorylated and its binding to microtubules was reduced (Tatebayashi et al., 2006; Matsumura et al., 1999; Dayanandan et al., 1999; Perez et al., 2000; Krishnamurthy and Johnson, 2004). However, the number of studies using a human model has been limited (Imamura et al., 2016; Jiang et al., 2018) and the pathological progression has not been entirely elucidated. Therefore, in this study we developed a patient-derived neuronal model using iPSC technology to recapture the disease pathology induced by the MAPT R406W mutation.

Taking advantage of the CRISPR/Cas9 gene-editing technology and the PiggyBac transposase system (Cong et al., 2013; Yusa et al., 2011), we established footprint-free isogenic WT (MAPT WT/+) or homozygous (MAPT R406W/R406W) iPSC lines from the original heterozygous R406W (MAPT R406W/+ ) patient-derived iPSC lines. These lines have a genetically identical background, making them important tools for assessing the genotype-phenotype relationship.

Using previously reported protocols, we generated cerebral organoids from our iPSC lines (Kadoshima et al., 2013; Lancaster et al., 2013). Building on this approach, we developed a method to isolate a homogeneous population of cortical neurons from the organoids. With our protocol, we were able to obtain a high percentage of cells expressing pan-neuronal markers (>85%–90%) and forebrain markers (~80%) without the use of transgenes (Zhang et al., 2013). There was also a high expression of NeuN, indicating the presence of mature neurons. Furthermore, we obtained a great number of neurons by dissociating a bulk of organoids, and it is possible to regulate this number by manipulating the number of organoids to be dissociated, making this method feasible for various types of analyses. To our knowledge, this is the first time dissociated organoids were used for disease modeling, and we clearly showed that the dissociated culture is suitable for both biochemical and immunochemical analyses. Hence, we demonstrated the utility of organoids for applications besides 3D modeling.

Using our neuronal culture, we first examined the phosphorylation state of the mutant tau. Abnormal phosphorylation of tau is a pathological hallmark of AD and other tauopathies, which is known to trigger tau pathology by reducing its affinity to microtubules, enhancing aggregation, altering its interactions with other proteins, and mis-sorting it from axons to the somatodendritic compartments in neurons (Wang and Mandelkow, 2016). Several studies have reported the aberrant phosphorylation status of R406W mutant tau, but results have been controversial. Results from in vitro experiments and non-neuronal cell lines indicated R406W mutant tau to be less phosphorylated than WT tau (Dayanandan et al., 1999; Matsumura et al., 1999; Perez et al., 2000; Sakaue et al., 2005; Tatebayashi et al., 2006), while studies using murine models or postmortem R406W patient brains claimed that they were hyperphosphorylated (Ikeda et al., 2005; Krishnamurthy and Johnson, 2004; Miyasaka et al., 2001; Tatebayashi et al., 2002). These controversies may have arisen because of the differences in tau solubility and the disease stages reflected in each model. In our human iPSC-derived neuronal model, R406W mutant tau was found to be less phosphorylated at specific epitopes. In addition to demonstrating reduced phosphorylation at T181 and S404, we newly identified S409 to be less phosphorylated in the mutant tau using western blot analyses. Using in vitro experiments, we further went on to reveal that the mutation impaired phosphorylation by PKA, RhoK, and GSK3β at these epitopes. In particular, GSK3β accounted for the overall reduction of phosphorylation, which is supported by the fact that T181, S404, and S409 are all potential phosphorylation sites by this kinase (Reynolds et al., 2000). However, it should be noted that the reduction of phosphorylation at S404 is debatable when taking into consideration a change in immunogenicity due to the mutation. Nevertheless, based on our findings and those from previous reports, it is highly plausible that the arginine-to-trypophan substitution makes tau less prone to phosphorylation by specific kinases, possibly due to some conformational change of the mutant tau. However, as the disease progresses, the mutant tau may become hyperphosphorylated, due to a mechanism not yet identified, as seen in the murine models and patients’ brains (Ikeda et al., 2005; Krishnamurthy and Johnson, 2004; Miyasaka et al., 2001; Tatebayashi et al., 2002).

Results regarding the efficiency of R406W mutant tau to bind and/or assemble microtubules compared with WT tau have also been controversial (DeFére et al., 2000; Hong et al., 1998; Dayanandan et al., 1999; Perez et al., 2000; Hasegawa et al., 1998; Krishnamurthy and Johnson, 2004). Here, we demonstrated that the mutant tau induces cellular phenotypes through the destabilization of microtubules. These phenotypes were rescued by treatment with the microtubule stabilizer EpoD, suggesting that the R406W mutation exerts negative effects on the physiological interaction of tau with microtubules.
A

<table>
<thead>
<tr>
<th>Patient #2</th>
<th>WT (201B7)</th>
<th>+/+</th>
<th>R406W/+</th>
<th>R406W/R406W</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAPI</td>
<td>MAP2</td>
<td>Tau</td>
<td>Merge</td>
<td></td>
</tr>
</tbody>
</table>

B

**Tau localization**

- **Dendrite**
- **Axon**

% of total tau

- 0%
- 20%
- 40%
- 60%
- 80%
- 100%
- 120%

C

<table>
<thead>
<tr>
<th>Patient #2</th>
<th>WT (201B7)</th>
<th>+/+</th>
<th>R406W/+</th>
<th>R406W/R406W</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAPI</td>
<td>MAP2</td>
<td>Tau</td>
<td>Merge</td>
<td></td>
</tr>
</tbody>
</table>

D

<table>
<thead>
<tr>
<th>Patient #2</th>
<th>WT (201B7)</th>
<th>+/+</th>
<th>R406W/+</th>
<th>R406W/R406W</th>
</tr>
</thead>
<tbody>
<tr>
<td>βIII-tubulin</td>
<td>MAP2</td>
<td>Tau</td>
<td>Merge</td>
<td></td>
</tr>
</tbody>
</table>

E

**Neurite Puncta**

- **Mock**
- **EpoD**

Neurite puncta per μm

- 0.0
- 0.2
- 0.4
- 0.6

(legend on next page)
Investigation at the cellular level revealed the mislocalization of tau to the dendrites and more punctuate axons in the mutant neurons, both of which have been observed in AD brains (Kowall and Kosik, 1987). Furthermore, there was a decrease in the number of mitochondria on the axons of the mutant neurons. Impairment of mitochondrial distribution has also been reported in an rTg4510 mouse model and in AD patient brains (Kopeikina et al., 2011), as well as in a P301L tau knockin mouse model, which has also interestingly found elevated amounts of hypophosphorylated tau (Rodriguez-Martín et al., 2016). In addition, live-imaging analysis showed that mitochondria in the mutant neurons were less stationary, and an increased percentage moved more in the retrograde direction away from the axons, which is consistent with the reduction of its number in the axons. This is in contrast to a previous study also using FTD patient-derived iPSC neurons, which reported that mitochondria in the mutant neurons were less mobile (Iovino et al., 2015). This discrepancy may be due to the differences in the mutations analyzed (R406W in this study versus P301L and N279K in Iovino et al., 2015). A previous report has demonstrated that microtubule-bound tau inhibits the motility of kinesin and dynein, and that the microtubule binding domain (MTBD) of tau is sufficient for this inhibition (Dixit et al., 2008). Thus, the impaired association of R406W tau with MTs may have promoted dynein to become overly motile, resulting in the increase in retrograde movement of mitochondria. In support of this, the axonal mitochondrial number in the mutant neurons was rescued with Epod treatment, confirming that MT destabilization induced by the mutant tau caused the transport defect.

Despite the numerous reports on tau pathology, the pathological cascade leading to neurodegeneration is still unknown. For example, the specific role of aberrant tau phosphorylation during pathological progression remains widely unexplored. In this study, we found that reduced tau phosphorylation makes tau more susceptible to calpain cleavage to generate 35-kDa N-terminal fragments. The calpain cleavage site of tau has been reported to be near the MTBD (Chen et al., 2018; Garg et al., 2011). Therefore, the resultant tau fragment either may have lost its ability to stabilize microtubules or have gained a toxic function to destabilize them, ultimately triggering the axonal phenotypes. Furthermore, although the cellular phenotypes could be observed in the mutant neurons at 30 days after dissociation, they could not be detected at an earlier time point. However, tau hypophosphorylation already occurred at 10 days post dissociation. Thus, abnormal tau phosphorylation seen in this study could be an early hallmark of the disease that triggers the consequent pathological events, such as MT destabilization, axonal dystrophy, and axonal transport defects.

Our study reports a previously unidentified molecular mechanism of tau pathology specifically induced by the R406W mutation. Understanding the cascade of pathological events leading to neurodegeneration using iPSC-derived models will help in defining targets for therapeutic development for a wide variety of tauopathies and other neurodegenerative diseases.

**EXPERIMENTAL PROCEDURES**

All experimental procedures for iPSCs derived from patients were approved by the Keio University School of Medicine Ethics Committee (approval no. 20080016).

**Cell Culture**

Peripheral blood cells from two patients with the MAPT R406W mutation were obtained (Ikeuchi et al., 2011), which were maintained in T cell medium, consisting of KBM502 medium (Kohjin Bio, Saitama, Japan) supplemented with Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher Scientific, Waltham, MA, USA). iPSCs were maintained on irradiated mouse embryonic fibroblasts or SNL 76/7 feeder cells in iPSC medium, consisting of DMEM/F12 medium (Wako, Osaka, Japan) supplemented with 0.08 mM MEM-Non Essential Amino Acid solution (Sigma-Aldrich, St. Louis, MO, USA), 2 mM L-glutamine, 20% (v/v) Knockout Serum Replacement (Thermo Fisher Scientific), 80 U/mL penicillin, 80 μg/mL streptomycin, 0.1 mM 2-mercaptoethanol, and 10 mg/mL basic fibroblast growth factor (PeproTech, Rocky Hill, NJ, USA). Feeder-free iPSCs were maintained on culture dishes coated with 0.25–0.5 μg/μL iMatrix-511 (Laminin-511E8) (Wako) in StemFit...
Generation and Dissociation of Cerebral Organoids

Organoids were generated from the iPSCs as previously described with slight modifications (Figure 2A; Lancaster et al., 2013; Kadoshima et al., 2013; described in Supplemental Experimental Procedures). Day-30 organoids were dissociated into single cells using the Nerve Cell Dissociation Medium A (KAC, Kyoto, Japan). 5 × 10^4 cells, 1 × 10^5 cells, and 5 × 10^5 cells were plated onto 60 µg/mL poly-L-ornithine (Sigma-Aldrich) and 10 µg/mL laminin (R&D Systems, Minneapolis, MN, USA)-coated 96-well, 48-well, and 12-well cell-culture plates, respectively (Greiner Bio-One, Kremsmünster, Austria) and cultured for another additional 30 days in Neurobasal medium supplemented with 1% (v/v) B27 supplement with vitamin A, 0.25% (v/v) Glutamax, and 1% (v/v) penicillin/streptomycin.

Immunofluorescence

The cells were fixed in 4% (w/v) paraformaldehyde for 15–20 min at room temperature, followed by washing in PBS three times for 5 min each. After permeabilization with 0.2% (v/v) Triton X-100 for 15–20 min, the cells were again washed in PBS three times for

![Figure 6. Mitochondrial Transport Defects in R406W Mutant Neurons](image)

(A) Quantification of live-imaging mitochondrial trafficking revealed mitochondria in the mutant neurons (patient #2) to be less stationary and moving more in the retrograde direction, when compared with those in the control neurons (n = 3 independent experiments; *p < 0.05, **p < 0.01, two-way ANOVA followed by Tukey's test).

(B and C) Representative pictures of fluorescent signals from iPSC-derived neurons transfected with Mito-eYFP and tdTomato, and immunostained with DAPI (C). Scale bars, 10 µm. There were fewer mitochondria on the axons of R406W mutant neurons compared with control neurons (B) (n = 3 independent experiments; **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA followed by Tukey's test), which recovered to the control level with EpoD treatment (n = 3 independent experiments; #p < 0.05, ##p < 0.01, ###p < 0.001, Student's t test).

Error bars indicate mean ± SEM.
Western Blot
Cells were dissociated from the culture plates and dissolved in lysis buffer containing 20 mM HEPES, 1 mM MgCl₂, 100 mM NaCl, 0.5% NP-40, 1 mM dithiothreitol, 0.4 mM Pefabloc (4-(2-aminoethyl)-benzene-sulfonyl fluoride), 10 μg/mL leupeptin, 10 mM NaF, and 10 mM β-glycerophosphate. After homogenization and sonication, the samples were centrifuged at 15,000 × g for 15 min at 4°C. For dephosphorylation, samples were treated with 20 U Lambda Protein Phosphatase (New England Biolabs, Ipswich, MA, USA) for 3 h at 30°C. The protein samples were diluted in 4× Laemmli Buffer (BioRad, Hercules, CA, USA) with 10 mM 2-mercaptoethanol and boiled at 95°C for 5 min. The lysates and the Tau Protein Ladder (rPeptide, Athens, GA, USA) were loaded onto Extra PAGE One Precast Gels 7.5%–12.5% (Nacalai Tesque, Kyoto, Japan). SDS-PAGE was performed at 120 V for 105 min. The proteins separated in the gel were transferred onto an Immobilon-P membrane (EMD Millipore). The membranes were blocked with 5% (w/v) skim milk for 30 min and incubated with antibodies diluted in Can Get Signal Immunoreaction Enhancer Solutions (Toyobo, Osaka, Japan). Signals on the membranes were visualized with the ECL Prime detection kit (GE Healthcare). Signals on the membranes were visualized with the ECL Prime detection kit (GE Healthcare). The images were acquired on an ImageQuant LAS 4000 (GE Healthcare).

For quantification, we normalized the levels of phosphorylated tau and tau fragments to total tau and full-length tau, respectively (see corresponding figure legends for further details). We have not included the quantification of total tau levels in our study because normalization with the highly variable GAPDH levels among different neuronal lines confounded our results.

Tau Localization Assay
The localization of tau was analyzed with an In Cell Analyzer 6000 (GE Healthcare). Dissociated neurons were immunostained with MAP2, βIII-tubulin, and tau, and the percentage of tau on MAP2- and βIII-tubulin-positive regions was quantified. Dendritic and axonal tau was defined as tau on MAP2-positive area and tau on βIII-tubulin-positive but MAP2-negative area, respectively.

Neurite Puncta Count
Confocal images of the neurites were obtained with the Zeiss LSM700 oil immersion 100× objective. The number of puncta on neurites was counted manually. For normalization, the length of the neurites was measured using the Fiji plugin Simple Neurite Tracer. Cultures were treated with or without 20 nM EpoD (Abcam) for 24 h for the rescue experiment.

Mitochondria Count
To visualize mitochondria, we transfected the dissociated neurons with pcDNA3 Mito-eYFP (kindly provided by Drs. T. Tomiyama and T. Umeda, Osaka City University) and tdTomato expression vectors. Confocal images of the mitochondria on the axons were taken with a Zeiss LSM700 oil immersion 63× objective. The numbers of mitochondria were counted manually. For normalization, the length of the neurites was measured using the Fiji plugin Simple Neurite Tracer.

Live-Imaging Mitochondrial Trafficking
Transfected neurons were visualized with the Olympus FV3000 confocal laser scanning microscope with a silicon-oil immersion 63× objective. A 1.6×–2.0× digital zoom was used for better viewing. Images were taken at 5-s intervals for a total of 100 frames.

Statistical Analysis
All data from at least three independent experiments are expressed as means ± SEM. All replicates are from different batches of organsoids that have been dissociated in separate experiments. GraphPad Prism 8 was used for statistical analysis. The normality of data was assessed using the Shapiro-Wilk test and variances were compared using the Brown-Forsythe test. Data were analyzed with the unpaired, two-tailed Student’s t test and one- or two-way ANOVA followed by Tukey-Kramer multiple-comparisons test, as indicated in the figure legends. Differences were considered significant when p < 0.05.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.stemcr.2019.08.011.

AUTHOR CONTRIBUTIONS

ACKNOWLEDGMENTS
We would like to thank Drs. T. Sone and M. Ishikawa for providing technical assistance and all members of the H.O. laboratory for their generous support. We are also thankful to Dr. S. Yamanaka (Kyoto University) for providing us with the 201B7 iPS line and Drs. T. Tomiyama and T. Umeda (Osaka City University) for providing us with the Mito-eYFP construct. This study was supported by the Acceleration Program for Intractable Disease Research Utilizing Disease-specific iPS Cells from the Japan Agency for Medical Research and Development (grant no. 19bm0804003h0003) and by the Scientific Research in Innovative Areas “Brain Protein Aging and Dementia Control” from the MEXT to H.O. The generation of the iPS lines (patient #3) was supported by grants from the National Institutes of Health (K01 AG046374 and P50 AG005681). H.O. is a founding scientist of K Pharma and SanBio. The authors declare no competing interests.
References


Krishnamurthy, P.K., and Johnson, G.V. (2004). Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind
microtubules in a neuronal cortical cell model. J. Biochem. 279, 7893–7900.


Supplemental Information

Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs

Figure S1

A) Patient #1

B) RW#1-9 RW#2-7

C) RW iPSC genome
Supplementary Figure 1. Generation of footprint-free iPSC clones with episomal vectors. Related to Figure 1.

(A) PCR analysis evaluating the removal of episomal vectors from the iPSC clones (P=passage number). Arrowheads indicate the bands for OriP (upper) from the episomal vector, and endogenous OCT4 (lower). 9 out of 11 clones and 5 out of 16 clones were free of episomal vectors for patient #1 and #2, respectively.

(B) G-banding karyotype analysis of representative iPSC clones.

(C) DNA sequence of iPSC clone confirming the excision of the selection cassette without any unintended mutations. The data representatively shows an iPSC clone derived from patient #1 (RW#1-9)
Supplementary Figure 2. Phosphorylation analysis of R406W mutant tau. Related to Figure 3.

(A-B) Western blot analysis investigating tau phosphorylation level at T181 (A). pT181 levels were significantly reduced in the R406W mutant samples derived from patient #3 relative to total tau (K9JA) (B) (n=3 independent experiments; one-way ANOVA followed by Tukey’s test).

(C-D) Western blot analysis investigating tau phosphorylation level at S404 (C). pS404 level was significantly reduced in the R406W mutant samples relative to total tau (K9JA) (D) (n=3 independent experiments; one-way ANOVA followed by Tukey’s test).

(E-F) Western blot analysis of Patient #3 iPSC-derived neurons with pan-tau antibody Tau5 (E) revealed an increase in the ratio of 48kD tau (lower band; arrowhead) to total tau (both 48kD and 55kD bands) (F) (n=3 independent experiments; Student’s t-test).

(G) Representative western blot analysis with total tau antibody Tau5 with or without dephosphorylating the samples with λ-phosphatase. The downwards shift of the 48kD and 55kD bands after dephosphorylation indicates that both bands represent phosphorylated forms of tau with different degrees of phosphorylation. Error bars indicate mean±SEM; *p<0.05, **p<0.01, ***p<0.001.
Figure S3

A) 

B) 

C) 

D) 

E) 

F) 

G) 

H) 

I) 

CHIR99021

WT  RW

Mock 0.1µM 1µM 10µM

Tau5 48kD band intensity

pS404 intensity

pS409 intensity

p-β-Catenin intensity

PP2A activity

Patient #2

WT (201B7) +/- R406W/+ R406W/- R406W

Patient #2
Supplementary Figure 3. Effect of kinases on the phosphorylation of R406W mutant tau. Related to Figure 3.

(A) Western blot analysis of the C-terminus fragment of WT and R406W (RW) tau after incubation with each respective kinase. In WT tau, S404 was directly phosphorylated by GSK3β and Cdk5, whereas S409 was directly phosphorylated by PKA and Rho-kinase (RhoK), both of which were impaired by the R406W mutation. GSK3β weakly phosphorylated WT and RW tau at S409 to a similar extent.

(B-C) Western blot analysis investigating the dose-dependent effects of GSK3β inhibitor CHIR99021 on the phosphorylation pattern of tau in WT (201B7) iPSC-derived neurons (B). Quantification of the ratio of 48kD tau to total tau (both 48kD and 55kD bands) revealed a dose-dependent increase of the ratio with CHIR99021 treatment (C) (n=3 independent experiments; one-way ANOVA followed by Tukey’s test).

(D-F) Western blot analysis of WT and R406W (RW) mutant tau conjugated with GFP and co-expressed with the respective kinases in COS-7 cells with tau antibodies detecting phosphorylation at S404 or S409 (D) and quantification of the phosphorylation levels (S404, E; S409, F). All of the kinases enhanced phosphorylation at S404 in WT tau, but no basal phosphorylation at S404 could be detected in RW tau, and none of the kinases were able to enhance the phosphorylation level (E). Co-expression of PKA or Rho-kinase enhanced the phosphorylation of WT tau at S409, but not with RW tau (F) (n=3 independent experiments; Student’s t-test).

(G-H) Western blot analysis of β-Catenin and p-β-Catenin (S33/S37/T41) levels in the iPSC-derived neurons (G). p-β-Catenin levels did not differ significantly among neuronal lines (H) (n=3 independent experiments).

(I) Measurement of phosphatase activity in the iPSC-derived neurons. The amount of phosphate released did not differ among neuronal lines, indicating that there was no significant difference in phosphatase activity (n=3 independent experiments).

Error bars indicate mean±SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Figure S4

A) 

WT (201B7) +/+ R406W/+ R406W/R406W

B) 

Patient #2

0.0 0.2 0.4 0.6

Relative to FL tau

C) 

WT (201B7) +/+ R406W/+ R406W/R406W

D) 

Patient #2

0.0 0.5 1.0 1.5

Relative to FL tau
Supplementary Figure 4. Tau fragmentation analysis in iPSC-derived neurons. Related to Figure 4.

(A-D) Western blot analysis of iPSC-derived neurons with total tau antibodies Tau5 (A) and Tau46 (C) revealed an increase in the ratio of tau fragments (bracket) to full-length tau (brace; tau5, B; tau46, D) (n=3–4 independent experiments, mean±SEM; *p<0.05, **p<0.01; One-way ANOVA followed by Tukey’s test).
Figure S5


B) Graph showing pT181 intensity relative to total tau in patient #2.

C) Graph showing pS404 intensity relative to total tau in patient #2.

D) Western blot analysis of tau5 and GAPDH in patient #2 with WT (201B7) +/+, R406W/+, and R406W/R406W genotypes.

E) Graph showing Tau5 48kD band intensity relative to total tau in patient #2.

F) Graph showing tau localization in dendrites and axons.

G) Graph showing neurite puncta per µm.
Supplementary Figure 5. Phenotype analysis of iPSC-derived neurons at earlier timepoints. Related to Figure 3, 4, 5.

(A-C) Western blot analysis investigating tau phosphorylation levels at T181 and S404 (A) in iPSC-derived neurons 10 days post dissociation. Phosphorylation levels at both epitopes were significantly reduced in the R406W mutant samples at this timepoint (T181, B; S404, C) relative to total tau (K9JA) (n=3 independent experiments).

(D-E) Western blot analysis with total tau antibody Tau5 (D) revealed an increase in the ratio of 48kD tau (arrowhead) to total tau (both 48kD and 55kD bands) in the R406W mutant samples (E) in iPSC-derived neurons 10 days after dissociation (n=3 independent experiments).

(F) Quantification of the percentage of tau on axons or dendrites of the neurons. The percentage of tau in either of the compartments did not significantly differ among neuronal lines (n=3 independent experiments).

(G) Quantification of the number of axonal puncta per neurite length (μm). The number of axonal puncta did not significantly differ among neuronal lines (n=3 independent experiments).

Error bars indicate mean±SEM. One-way ANOVA followed by Tukey’s test was performed; *p<0.05, **p<0.01, ***p<0.001.
**Table S1. iPSC donor information Related to Figure 1.**

<table>
<thead>
<tr>
<th></th>
<th>Patient #1*</th>
<th>Patient #2*</th>
<th>Patient #3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td><strong>Age at onset</strong></td>
<td>50</td>
<td>47</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Age at examination</strong></td>
<td>67</td>
<td>48</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Age at biopsy</strong></td>
<td>N/A</td>
<td>N/A</td>
<td>70</td>
</tr>
<tr>
<td><strong>Origin</strong></td>
<td>Peripheral mononuclear blood cell</td>
<td>Peripheral mononuclear blood cell</td>
<td>Fibroblast</td>
</tr>
<tr>
<td><strong>Reprogramming method</strong></td>
<td>Episomal</td>
<td>Episomal</td>
<td>Sendai virus</td>
</tr>
<tr>
<td><strong>Gene-editing</strong></td>
<td>WT, homo</td>
<td>WT, homo</td>
<td>WT</td>
</tr>
</tbody>
</table>

N/A = not available, WT = wild-type, homo = homozygous

*Modified from Ikeuchi et al., 2011
Supplemental Experimental Procedures

Generation of iPSCs from the patient blood cells

iPSCs were generated from peripheral blood mononuclear cells (PBMCs) or T cells as previously described (Okita et al., 2013, Ichiiyanagi et al., 2016, Nakamoto et al., 2018). Briefly, PBMCs were isolated by centrifuging at 15000 g for 20 minutes at room temperature, using the BD VACUTAINER CPT (BD, Franklin Lakes, NJ, USA). Remaining PBMCs were maintained in T cell medium and cultured as T cells. Episomal vectors pCE-hOCT3/4, pCE-hSK, pCE-hUL, pCE-mP53DD (all 0.63 µg), which express OCT3/4, SOX2, and KLF4, L-MYC and LIN28, and p53 dominant negative mutant, respectively, as well as pCXB-EBNA1 (0.5 µg), which express EBNA1 (AddGene IDs: 41813, 41814, 41855, 41856, 41857) were electroporated into 3 × 10^6 PBMCs or T cells using a Nucleofector 2b Device (Lonza, Basel, Switzerland, V-024 program) with an Amaxa Human T-cell Nucleofector kit (Lonza) according to the manufacturer's instructions. 2 days after transfection, an equal volume of iPSC medium was added to the culture without aspirating the T cell medium. The medium was completely replaced with iPSC medium 4 days after transfection. Colonies with a human embryonic stem cell (ESC)-like morphology were picked up between 26~33 days after transfection and cultured further for cultivation and evaluation. All experimental procedures for iPSCs derived from patients were approved by the Keio University School of Medicine Ethics Committee (approval no. 20080016).

Generation of cerebral organoids

Organoids were generated from the iPSCs as previously described with slight modifications (Figure 2A; Lancaster et al., 2013; Kadoshima et al., 2013). Briefly, on day 0 of organoid culture, iPSCs were dissociated and 3 × 10^4 cells were aggregated into embryoid bodies (EBs) in low attachment V-shaped 96-well plates (Sumitomo Bakelite, Tokyo, Japan). For 6 days, the EBs were maintained in StemFit AK02N medium supplemented with 30 µM Y-27632, as well as 5 µM SB431542 and 2.5 µM IWP-2 to specifically induce them into the forebrain region of neural tissue. On day 6, the medium was changed to neural induction medium consisting of 1% (v/v) N2 Supplement (Thermo Fisher Scientific), 1% (v/v) Glutamax (Thermo Fisher Scientific), 1% (v/v) MEM-NEAA, 2.5 µM IWP-2, 5 µg/ml sodium heparan sulfate (Sigma-Aldrich), and 1% (v/v) penicillin/streptomycin in DMEM/Ham’s F-12 medium (Thermo Fisher Scientific). On day 9, the EBs were transferred into Ultra-Low Attachment surface 6 well plates (Corning, Corning, NY, USA), grown in differentiation media composed of a 1:1 mixture of DMEM/Ham’s F-12 medium and Neurobasal medium (Thermo Fisher Scientific), supplied with 1% (v/v) N2 supplement, 2% (v/v) B27 supplement without vitamin A (Thermo Fisher Scientific), 100 µM 2-mercaptoethanol, 2.5 µg/ml insulin (Wako), 1% (v/v) Glutamax, 0.5% (v/v) MEM-NEAA, and 1% (v/v) Matrigel (Corning). The plates containing the EBs were maintained on a shaker to enhance nutrient and oxygen absorption. On day 15, the medium was changed to differentiation medium consisting of B27 supplement with vitamin A (Thermo
Fisher Scientific). The medium was changed every 5~7 days from then on.

**Pluripotency check of iPSC clones**

The iPSC clones were immunostained for pluripotency markers alkaline phosphatase using SIGMAFAST BCIP/NBT (Sigma-Aldrich) according to the manufacturer’s instructions, and anti-TRA-1-60 (mouse, 1:500 dilution, EMD Millipore, Billerica, MA, USA).

**Karyotype analysis**

G-banding analysis of the iPSC lines was conducted by the LSI Medience Corporation (Tokyo, Japan).

**Construction of targeting vectors and Cas9 vector**

The MAPT locus containing exon 13 with or without the R406W mutation was cloned from the patient genome into the pCR-Blunt II-TOPO vector (Thermo Fisher Scientific) by PCR using the following primers: forward TTTTTGGCTTTACCAGATGCTCA, reverse TCATTACTGAGAAGGGGTGGTGGA. The PCR conditions are as follows: 35 cycles of 98℃ for 10s, followed by 68℃ for 3 min 30s. The PrimeSTAR Max DNA Polymerase (Takara, Kusatsu, Japan) was used. A 2-kb 5´arm and 5-kb 3´arm consisting of exon 13 with the mutation site were cloned individually into separate entry vectors by PCR using the following primers: 5´arm forward, AACTTTGTATAATAAGTTGTGACTGAGTGGGTCTGGATAGG, reverse CAGACTATCTTTCTAGGGTTAAGTTTCTTGTGATCCCTCCAG, 3´arm forward, ATGATTATCTTTCTAGGGTTAATGATCACTGTCTCGG, reverse CAACCTTGTATAGAAAAGTTGCTAAGGGTGCGTGGAAAGA. The PCR conditions are as follows: 98℃ for 1 min, followed by 20 cycles of 98℃ for 10s and 68℃ for 2 min (5´arm) or 5 min (3´arm). Using the GeneArt Seamless Cloning and Assembly Kit (Thermo Fisher Scientific), these entry vectors, along with another entry vector consisting of a selection cassette with Puromycin-ΔTK driven by a mouse PGK promoter and PiggyBac inverse terminal repeats (ITRs) at both ends (Figure 2A), were assembled into a single destination vector.

The Cas9 expression plasmid vector pSPCas9(BB)-2A-Puro (PX459) was obtained from AddGene (ID: 48139). Complementary oligonucleotides encoding sgRNA were annealed and cloned into the BbsI site in the Cas9 vector. The sequences of the oligonucleotides are as follows: upper, CTTAAATGATCAGTGTCTCTGGG, lower, AAACGAGACAGTGATGATCATTTTAAGC.

**Transfection of targeting vector into iPSCs**

Feeder-free iPSCs were pre-treated with 10 µM Y-27632 (EMD Millipore) overnight to prevent apoptosis induced by dissociation (Watanabe et al., 2007). The iPSCs were dissociated into single cells with Tryple Select (Thermo Fisher Scientific). The targeting vector with or without the R406W mutation and the Cas9
expression vector were electroporated into $1 \times 10^6$ iPSCs using NEPA21 (NepaGene, Chiba, Japan). Transfected cells were plated onto iMatrix-511-coated 60 mm dishes (Iwaki, Chiba, Japan). Y-27632 was removed from the culture 2 days after the transfection. Cells were treated with 0.75–0.8 µg/µl puromycin on days 2, 3, 6, and 8 after plating.

Colonies with a human ESC-like morphology were picked up and DNA from each colony was extracted using the DNeasy Blood & Tissue Kit (QIAGEN, Hilden, Germany). PCR analysis evaluating the knock-in of targeting vectors was performed using the following primers: forward, GCGTCCAGAAAGGTATAGG, reverse GTACGTAAAAGAATTGTTTGTGA. The DNA of the clones in which knock-in occurred was analyzed by Sanger sequencing with the 3130xl Genetic Analyzer (Applied Biosystems, Waltham, MA, USA) to check the mutation site.

**Excision of PiggyBac cassette from iPSCs**

Feeder-free iPSCs pre-treated with 10 µM Y-27632 overnight were dissociated into single cells with Tryple Select (Thermo Fisher Scientific). 1 µg PBx (Excision Only PiggyBac Transposase; Funakoshi, Tokyo, Japan) was transfected into $1 \times 10^6$ iPSCs with the GeneJuice Transfection Reagent (EMD Millipore) and plated onto iMatrix-511-coated 10 cm dishes (Iwaki). DNA extraction and PCR analysis were performed as described above.

**Generation of cerebral organoids**

Organoids were generated from the iPSCs as previously described with slight modifications (Figure 2A; Lancaster et al., 2013; Kadoshima et al., 2013). Briefly, on day 0 of organoid culture, iPSCs were dissociated and $3 \times 10^5$ cells were aggregated into embryoid bodies (EBs) in low attachment V-shaped 96-well plates (Sumitomo Bakelite, Tokyo, Japan). For 6 days, the EBs were maintained in StemFit AK02N medium supplemented with 30 µM Y-27632, as well as 5 µM SB431542 and 2.5 µM IWP-2 to specifically induce them into the forebrain region of neural tissue. On day 6, the medium was changed to neural induction medium consisting of 1% (v/v) N2 Supplement (Thermo Fisher Scientific), 1% (v/v) Glutamax (Thermo Fisher Scientific), 1% (v/v) MEM-NEAA, 2.5 µM IWP-2, 5 µg/ml sodium heparan sulfate (Sigma-Aldrich), and 1% (v/v) penicillin/streptomycin in DMEM/Ham’s F-12 medium (Thermo Fisher Scientific). On day 9, the EBs were transferred into Ultra-Low Attachment surface 6 well plates (Corning, Corning, NY, USA), grown in differentiation media composed of a 1:1 mixture of DMEM/Ham’s F-12 medium and Neurobasal medium (Thermo Fisher Scientific), supplied with 1% (v/v) N2 supplement, 2% (v/v) B27 supplement without vitamin A (Thermo Fisher Scientific), 100 µM 2-mercaptoethanol, 2.5 µg/ml insulin (Wako), 1% (v/v) Glutamax, 0.5% (v/v) MEM-NEAA, and 1% (v/v) Matrigel (Corning). The plates containing the EBs were maintained on a shaker to enhance nutrient and oxygen absorption. On day 15, the medium was changed to differentiation medium consisting of B27 supplement with vitamin A (Thermo Fisher Scientific). The medium was changed every 5–7 days from then on.
Phosphorylation analysis of tau

Human Tau cDNAs (0N3R, WT and R406W) were synthesized, and subcloned into pEGFP-c1 mammalian expression vector. The C-terminus of Tau (308-351 aa; VVSGDTSP(R/W)HLNSVSTGSIDMVQSLADEVSASLAKQGL) was subcloned into pGEX-2T E. coli expression vector. GST-PKAc (#01-127) and GST-GSK3β (#04-141) were purchased from Carna Biosciences (Kobe, Japan). GST-Rho-kinase-cat, GST-CDK5, and GST-p35 were expressed in Sf9 cells using a baculovirus system and purified using glutathione Sepharose beads (Amano et al., 1999).

For in vitro analysis, GST-Tau-C (1 μM) was incubated with each kinase (30 nM) in a reaction mixture (25 mM Tris-HCl at pH 7.5, 1 mM EDTA, 1 mM DTT, 5 mM MgCl₂, and 50 μM ATP) for 30 min at 30°C. The reaction mixtures were boiled in SDS sample buffer and subjected to western blot analysis.

Plasmids encoding Tau and each kinase were transfected into COS7 cells using the Lipofectamine® 2000 reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol. The cells were lysed with SDS sample buffer and subjected to western blot analyses.

Immunofluorescence antibodies

The following primary antibodies and dilutions were used: anti-TBR1 (rabbit, Abcam, Cambridge, UK, ab31940, 1:200 dilution), anti-MAP2 (chicken, Abcam ab5392, 1:10000 dilution), anti-βIII-tubulin (rabbit, Abcam, ab18207, 1:1000 dilution), anti-FOXG1 (rabbit, Abcam, ab18259, 1:500), and anti-tau (RTM38, Fujifilm Wako Pure Chemical, Osaka, Japan; rat, 1:5000 dilution). The following day, the cells were incubated with secondary antibodies for 1 hour at room temperature. Secondary antibodies used include Goat Alexa 488, 555, and 647 conjugates (Thermo Fisher Scientific, 1:500 dilution). Nuclear staining was performed with the Cellstain DAPI solution (DOJINDO, Kumamoto, Japan, 1:1000 dilution) for 15~20 minutes at room temperature.

Western blot antibodies and reagents

The following primary antibodies were used: anti-tau (K9JA) (Agilent Technologies, Santa Clara, CA, USA, 1:10000 dilution), Tau5 (mouse, 1:2000 dilution), Tau12 (mouse, 1:10000 dilution), Tau46 (mouse, Cell Signaling Technology, Beverly, MA, USA, 4019, 1:2000 dilution), anti-Tau-pT181 (rat, Cell Engineering Corporation, Osaka, Japan, 1:1000 dilution), anti-Tau-pS409 (rabbit, 1:1000 dilution; Amano et al., 2003), anti-β-Catenin (rabbit, Cell Signaling Technology, 8480, 1:2000 dilution), anti-p-β-Catenin (S33/S37/T41) (rabbit, Cell Signaling Technology, 9561, 1:1000 dilution), and anti-GAPDH (rabbit, Sigma-Aldrich, G9545, 1:10000 dilution).

For protease inhibition, dissociated neurons were pre-treated with either 120 μM Z-VAD-FMK (Peptide Institute, Osaka, Japan), pan-caspase inhibitor, or 250 μM ALLN (Nacalai Tesque), pan-calpain inhibitor, for 24 hours before cell lysis.
For kinase inhibition, dissociated neurons were pretreated with 1 µM KT5720 (Tocris), 10 µM Y27632 (Merck), 20 µM SB216763 (Tocris), 20 µM Roscovitine (Sigma), or CHIR99021 (0.1 µM, 1 µM, or 10 µM) for 24 hours before cell lysis.

**Phosphatase activity assay**

Phosphatase activity was measured using the Serine/Threonine Phosphatase Assay System (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Briefly, cells were lysed in phosphatase storage buffer, which consisted of 0.05M Tris-HCl (pH 7.0), 0.1mM EGTA, 0.1% 2-ME, 0.4 mM Pefabloc (AEBSF), and 10 µg/ml leupeptin and endogenous phosphate was removed as using the spin columns provided in the assay kit. To measure PP2A activity, the reaction premix, which consists of 5x PP2A reaction buffer (250 mM imidazole (pH 7.2), 1mM EGTA, 0.1% 2-ME, 0.5mg/ml BSA, 0.4 mM Pefabloc (AEBSF), and 10 µg/ml leupeptin), synthetic phosphopeptide, and the lysate samples, was prepared in duplicate in 96 well plates and allowed to react for 10 min at 37°C. Reaction was stopped with the addition of Molybdate Dye/Additive mixture and the dye color was allowed to develop for 15–30 min at room temperature. Absorbance was measured at 600 nm with the Glomax Microplate Reader (Promega) to assess the amount of phosphate released.

**List of plasmids used in this study**

<table>
<thead>
<tr>
<th>Plasmid name</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>pSPCas9(BB)-2A-Puro (PX459)</td>
<td>Mammalian expression vector, CBh promoter, Cas9</td>
</tr>
<tr>
<td>pGEX-2T-Tau-C-WT/R406W</td>
<td>E.coli expression vector, tac promoter, GST-Tau-C (human 0N3R, 308-351 aa)</td>
</tr>
<tr>
<td>pEGFP-c1-Tau-WT/R406W</td>
<td>Mammalian expression vector, CMV promoter, EGFP-Tau (human 0N3R, 1-351 aa)</td>
</tr>
<tr>
<td>pCGN-HA-GSK3B-CA</td>
<td>Mammalian expression vector, CMV promoter, HA-GSK3B-CA (human)</td>
</tr>
<tr>
<td>pEF-BOS-GST-PKA-CA</td>
<td>Mammalian expression vector, EF-1α promoter, GST-PKA-CA (mouse)</td>
</tr>
<tr>
<td>pEF-BOS-GST-Rho-kinase-cat</td>
<td>Mammalian expression vector, EF-1α promoter, GST-Rho-kinase catalytic region (bovine)</td>
</tr>
<tr>
<td>pEF-BOS-GST-CDK5</td>
<td>Mammalian expression vector, EF-1α promoter, GST-CDK5 (human)</td>
</tr>
<tr>
<td>pEF-BOS-GST-p35</td>
<td>Mammalian expression vector, EF-1α promoter, GST-p35 (human)</td>
</tr>
<tr>
<td>pcDNA3-Mito-eYFP</td>
<td>Mammalian expression vector, CMV promoter, Mito-eYFP</td>
</tr>
<tr>
<td>ptdTomato</td>
<td>Mammalian expression vector, CMV promoter, tdTomato</td>
</tr>
</tbody>
</table>
Supplemental References

